

A reproducible enteric phage community improves blood glucose regulation in an obesity mouse model

Xiaotian Mao¹, Sabina Birgitte Larsen¹, Line Sidsel Fisker Zachariassen², Anders Brunse³, Signe Adamberg⁴, Josue Leonardo Castro Mejia¹, Kaarel Adamberg^{4,5}, Dennis Sandris Nielsen¹, Axel Kornerup Hansen², Camilla Hartmann Friis Hansen², Torben Sølbeck Rasmussen^{1*}

Author affiliations

¹ Section of Microbiology and Fermentation, Dept. of Food Science, University of Copenhagen, Frederiksberg, Denmark

² Section of Experimental Animal Models, Dept. of Veterinary and Animal Sciences, University of Copenhagen, Frederiksberg, Denmark

³ Section of Comparative Pediatrics and Nutrition, Department of Veterinary and Animal Sciences, University of Copenhagen, Frederiksberg, Denmark

⁴ Department of Chemistry and Biotechnology, Tallinn University of Technology, Tallinn, Estonia

⁵ Center of Food and Fermentation Technologies, Tallinn, Estonia

*Address correspondence to dn@food.ku.dk (+45 35 33 32 87) / torben@food.ku.dk (+45 35 32 80 73), Rolighedsvej 26 4th floor, 1958 Frederiksberg C, Denmark.

Keywords: Fecal virome transplantation, gut microbiome, type-2-diabetes, NAFLD, phage therapy, obesity, metabolic syndrome

Abstract

Introduction: Recent evidence suggest a link between gut microbiome dysbiosis and metabolic syndrome, including type-2-diabetes, obesity, and non-alcoholic fatty liver disease (NAFLD). Fecal microbiota transplantation (FMT) has been explored as a way to restore a healthy gut microbiome in obese patients but poses safety concerns. The wide use of FMT is limited by safety concerns about transferring the entire fecal microbiome from one individual to another. Fecal virome transplantation (FVT) is a safer alternative that transfers bacteriophages without bacterial transfer, but still carries the risk of eukaryotic virus infection. Therefore, a safer and more effective tool for modulating gut microbiome is needed.

Methods: We explored the potential of implementing three alternative FVT techniques with increased safety established in a recent study (eukaryotic viruses were either eliminated or inactivated) to ameliorate symptoms associated with a diet-induced obesity mouse model. Male mice were fed with an *ad libitum* high-fat diet before being euthanized (23 weeks of age) and received the different FVT treatments twice with one week of interval. Body weight was measured, oral glucose tests were performed, feces were sampled frequently, and liver, fat pads, mesenteric lymph node, and blood serum were sampled at termination of study.

Results: FVT treatments had no effect on weight gain or the amount of epididymal white adipose tissue. Mice given regular untreated FVT (FVT-UnT) had a significant ($p < 0.05$) drop in the pathological score of their liver tissue when compared to HFD-control mice. Mice treated with a chemostat propagated fecal virome (FVT-ChP, eukaryotic viruses eliminated by dilution) improved their blood glucose regulation significantly ($p < 0.05$) compared to HFD-control mice. Gut microbiome analysis of both the bacterial and viral component suggested that bacteriophage-mediated modulation of the gut microbiome could be a driving factor for the observed effects.

Conclusions: These results may lay the ground to develop safer bacteriophage-based therapeutic tools to restore the dysbiotic gut microbiome associated with metabolic syndrome.

Introduction

Over the past century, obesity has become a chronic metabolic disease affecting adults and children worldwide due to high-calorie foods and inadequate exercise resulting from modern lifestyles¹. Especially, type-2-diabetes is the most common type of diabetes that are associated with obesity^{2,3}. Although many obese patients can obtain substantial weight-loss, only few are able to maintain their body weight long-term⁴. It is increasingly accepted that a dysbiotic gut microbiome is highly associated to obesity^{5,6} and with recurrent obesity⁷. Ridaura *et al.* revealed that fecal microbiota transplantation (FMT) from a human donor that suffered from obesity to germ-free mice resulted in a significantly increased body weight compared to germ-free mice that received FMT from a lean human donor^{7,8}. While the majority of clinical experience with successful FMT comes from treating recurrent *Clostridioides difficile* infections, the application of FMT to treat obesity and type-2-diabetes remain exploratory and with limited effects^{9–11}. Although the beneficial effects of FMT on intestinal pathology are well established¹², safety concerns remain associated with FMT. This was exemplified by the death of a patient in 2019 that was caused by a bacterial infection after FMT¹³. In addition to bacteria, the fecal matrix of FMT includes archaea, eukaryotes, viruses, and gut metabolome, any of which may be responsible for both the beneficial and detrimental effects of FMT¹⁴. Therefore, reducing the complexity of the donor fecal matrix, while maintaining its therapeutic efficacy, would be an improvement in regard to the safety in clinical settings.

The gut virome is composed of predominantly bacteriophages (in short phages) that are viruses which infect bacteria in a host-specific manner^{15,16}. This ubiquitous viral entity is also prevalent in the mammalian gut microbiome and is thought to play a key role in shaping and maintaining the composition of the gut microbiome as well as affecting host metabolism^{17,18}. Fecal virome transplantation (FVT, sterile filtrated donor feces) has been suggested as an alternative to FMT^{16,19}. Patients suffering from recurrent *Clostridioides difficile* infections that were treated with FVT had a cure rate comparable to FMT treatment^{20,21}, and FVT has shown to alleviate symptoms of type-2-diabetes and obesity in mice²², as well as preventing the onset of necrotizing enterocolitis in preterm piglets²³. FVT has also reported to restore the gut microbiome in mice after initial disturbance with antibiotics²⁴. Taken together, these findings illustrate the promising application of FVT as a treatment targeting a variety of diseases associated with gut microbiome dysbiosis. No studies have yet reported any severe adverse effects associated to FVT^{21–23}, however, it remains critical to ensure that no harmful microorganisms are transferred to humans when treated with FVT. The centrifugation and filtration steps applied for preparing FVT¹⁶, cannot separate phages from eukaryotic viruses due to similar size. Screening assays can be used to detect known pathogenic viruses, but during recent years it has become evident that the human gastrointestinal tract harbors hundreds of eukaryotic viruses of unknown function^{17,25,26}. Although most of these viruses are likely harmless, it should not

be neglected that they might play a key role in later disease development, as seen for the human papillomavirus (HPV) that can induce cervical cancer years after infection²⁷. In two recent studies, we sought to enhance the safety of FVT by developing methodologies that selectively inactivate²⁸ or remove the eukaryotic viruses from the fecal matrix²⁹, while preserving an active gut phage community. In order to achieve this, we utilized the differences in key characteristics between eukaryotic viruses and phages^{28,29}: most eukaryotic viruses are enveloped RNA viruses^{30–32}, and the majority of phages are non-enveloped DNA viruses^{32,33}. Solvent detergent treatment was used to inactivate enveloped viruses³⁴, a compound (pyronin Y) that specifically binds to RNA^{35,36} was applied to inactivate RNA viruses, and an optimized chemostat fermentation of fecal inoculum removed the eukaryotic viruses by dilution²⁹. Some of these modified FVT viromes showed promising results in treating *Clostridioides difficile* infections in a mouse model²⁸, which represent a simple disease etiology that mainly is caused by the toxin producing *C. difficile*³⁷.

In this study we used the same modified FVTs²⁸ to investigate their treatment efficacy in a diet-induced obesity model³⁸ that represents a more complex gut microbiome associated disease, compared to *C. difficile* infections.

Results

The aim of this study was to assess potential alleviating effects of symptoms associated with type-2-diabetes and obesity by FVTs that was modified by inactivating or removing the eukaryotic viral component of the fecal viromes. We applied a solvent/detergent method (FVT-SDT) to inactivate enveloped viruses by dissolving their lipid membrane, pyronin Y treatment (FVT-PyT) to prevent RNA virus replication, and a chemostat propagated virome (FVT-ChP) to remove eukaryotic viruses by dilution. The different modified viromes were compared with an untreated virome (FVT-UnT) and saline (control) treatment of the mice fed either a high-fat (HFD-control) or low-fat diet (LFD-control). All the transferred fecal material used in the study was from the same mixed donor material.

A chemostat propagate virome improves the blood glucose clearance

The weight gain percentage of the mice was measured to evaluate the effect of the different treatments on body weight. The HFD-control mice significantly ($p < 0.05$) increased their body weight, epididymal white adipose tissue (eWAT), and insulin resistance compared to the LFD-control mice (Figure 1A, 1B, & 1C), hence, emphasizing that the diet-induced-obesity model had progressed as expected. However, the body weight and size of the eWAT was not improved by any of the FVT treatments when compared with the HFD-control group (Figure 1A and 1B). Oral glucose tolerance tests (OGTT) were performed after 13 weeks (Figure S1) and 18 weeks on high-fat diet to evaluate the insulin sensitivity of the mice. The OGTT measures of the HFD-control mice was not increased

compared to the LFD-control mice at week 13 (18 weeks of age) which indicated that the model was not yet fully effective at this stage. Neither did any of the FVT treatments show improved OGTT measured when compared with the HFD-control (Figure S1). All mice fed high-fat diet had a hampered clearance of blood glucose compared with the LFD-control mice in the first 15 min after the oral glucose administration (Figure 1D). At study week 18 (23 week of age) the blood glucose levels of mice treated with the chemostat propagated virome (FVT-ChP) decreased sharply from 30 min to 60 min after glucose administration. This highlighted a significantly ($p = 0.0429$) improved blood sugar regulation of the FVT-ChP treated mice 10 weeks after 2nd FVT treatment, compared with the HFD-control mice (Figure 1C). Although the level of blood glucose of FVT-ChP was influenced by the HFD (Figure 1C & 1D), the administration of the chemostat propagated enteric virome seemed to have contributed to an improved insulin sensitivity.

A non-alcoholic fatty liver disease (NAFLD) activity score was assessed by histopathology to evaluate the consequences of a high-fat diet on liver status (Figure 1E & Figure S2). The FVT-UnT treated mice had a significantly ($p < 0.05$) lower pathological score compared to the HFD control mice (Figure 1E). The pathological score of HFD-control, FVT-ChP, FVT-SDT, and FVT-PyT presented a significant increase ($p < 0.05$) compared with LFD-control mice.

Chemostat propagated virome treatment altered immune cell composition in fat tissue

Fluorescence-activated cell sorting (FACS) was performed to evaluate the presence of immune cells in fat tissue (Figure 2A-L) and the mesenteric lymph node (Figure S4) at termination (23 weeks of age). The mice that were treated with the chemostat propagated virome (FVT-ChP) expressed a significant ($p = 0.0331$) decrease in the number of central memory T cells CD4 (CD44+CD62I+/CD4) compared with the LFD-control (Figure 2A). The high-fat fed mice all appeared with a significant ($p < 0.05$) increase in the level of activated M1 macrophages (CD11c+/F4.80) when compared with the LFD-control group (Figure 2L). The mice treated with the untreated FVT (FVT-UnT) showed a decrease in cell number of central memory T cells CD8 ($p = 0.00314$, CD44+CD62I/CD8), dendritic cells ($p = 0.0375$, CD11c+/CD45), and M1 macrophages ($p = 0.0109$, CD11c+/F4.80) compared to the HFD-control mice (Figure 2D, 2J, & 2L). The FVT-ChP treated mice had significant ($p = 0.00371$, $p = 0.00433$) elevated levels of dendritic cells compared with FVT-UnT mice (Figure 2J).

Transplantation of modified fecal viromes shifted the gut microbiome composition

The gut bacterial and viral composition of the mice were investigated at three time points: their arrival at our housing facilities (5 weeks of age), 1 week after 2nd FVT (13 weeks of age), and at termination (23 weeks of age). Interestingly, the mice treated with the chemostat propagated virome (FVT-ChP) had significantly ($p < 0.05$) changed their gut bacterial composition compared with the HFD-control

mice and FVT-UnT treated mice at termination. Also the FVT-UnT treated mice had significantly ($p < 0.05$) changed their bacterial component at termination when compared to the HFD-control. (Figure 3B & Table S1). At termination, the relative abundance of the bacterial genus *Allobaculum* was significantly higher in FVT-ChP ($p = 0.04715$) and LFD_control ($p = 0.00144$) when compared with the HFD-control mice.

At the arrival to our housing facility the bacterial component of the mice appeared similar when analyzing the Shannon diversity index (bacterial diversity) and Bray-Curtis dissimilarity (bacterial composition) (Figure 3A and 3B). The high-fat diet had clearly ($p < 0.05$) affected the bacterial component 1 week after 2nd FVT and at termination, compared to the mice fed low-fat diet (Figure 3A & 3B). The relative abundance of *Bifidobacterium* in high-fat diet fed mice at termination was significantly lower ($p < 0.05$) than LFD-control mice, suggesting that the high-fat diet had influenced the relative abundance of *Bifidobacterium*. Meanwhile, FVT-ChP, FVT-SDT, FVT-PyT, and HFD-control mice were all composed with a significant higher ($p < 0.05$) relative abundance of *Lactobacillus* and *Lactococcus* compared with LFD-control mice.

None of the FVT treatments had affected the gut viral diversity, expressed by the Shannon diversity index, however, the viral composition (Bray-Curtis dissimilarity) of mice treated with FVT-ChP, FVT-UnT, and FVT-SDT were all significantly ($p < 0.05$) different when compared with the HFD-control mice (Figure 4A, 4B, & Table S2). More than 21.8% of the relative viral abundance could not be classified (Figure 5C). The main viral taxa represented the order *Caudovirales* (including *Podo*-, *Myo*-, and *Siphoviridae*) and the viral family of *Microviridae*. Analysis of the differential viral abundance was performed on both the level of viral contigs (vOTUs) and their predicted bacterial hosts (Figure S5 and Figure S6) to support the observed differences in the viral composition. Especially the viruses belonging to the family *Microviridae* and order *Caudovirales* were observed with significant ($p < 0.05$) differences in their relative abundance (Figure S5) while significant ($p < 0.05$) differences of the relative abundance of the predicted bacterial hosts belonged to the genera of *Parabacteroides*, *Bacteroides*, *Prevotella*, and *Akkermansia* (Figure S6) when comparing FVT-ChP and -UnT treated mice with the HFD-control at termination. This suggests that treatment with the modified viromes also affected the viral gut component of the mice over a span of 18 weeks.

Discussion

Here we addressed the safety considerations associated with the eukaryotic viral component in fecal virome transplantation (FVT) that previously have shown to alleviate symptoms of type-2-diabetes²². Recent developed methodologies were applied to either inactivate or remove the eukaryotic component of FVT while maintaining an active enteric phage community^{28,29}. The potential effects of

alleviating symptoms of type-2-diabetes and obesity with these modified FVTs were investigated in this present study using a diet-induced obesity mouse model. The modified FVTs represented a chemostat propagated enteric virome (FVT-ChP), solvent/detergent treated fecal virome for inactivating enveloped viruses (FVT-SDT), and chemically binding of the compound pyronin Y for hindering replication of RNA viruses (FVT-PyT). Their potential alleviating effect on the diet-induced obesity model were compared with an untreated fecal virome (FVT-UnT) and a saline treatment of high-fat diet (HFD-control) and low-fat diet (LFD-control) fed control mice.

Regular FVT (equivalent to FVT-UnT) has previously been reported to reduce weight again and normalize the blood glucose regulation in a similar diet-induced obesity model²². However, we could not replicate these results in our study, since no clear differences in weight gain and epididymal white adipose tissue size were observed when comparing any of the FVT treatment groups with HFD control mice (Figure 1A & 1C). The FVT-UnT treated mice neither expressed improved phenotype in regard to their blood glucose regulation (Figure 1C & 1D). This is likely explained by gut microbiome differences in the donor materials that are driven by various parameters at the mouse vendor facilities which indeed challenges reproducibility³⁹⁻⁴². Surprisingly, mice treated with the chemostat propagated virome (FVT-ChP) expressed a significantly ($p < 0.05$) improved blood glucose regulation compared with the HFD-Control mice. Considering the reproducibility of enteric phageome propagated with a chemostat setup (inoculated with either mouse and human inoculum)²⁹, this approach may constitute future perspectives to enhance the reproducibility of FVT-based studies. Most of the drug-based treatments for chronic diseases are long-term or periodic^{43,44}, but this study only treated mice with FVT twice. Compared with the phenotypical changes induced by a long-term high-fat diet, the two FVT treatments may be insufficient, raising the question if the number of FVT treatments should be increased in future intervention studies.

Histopathological assessment of the mouse liver tissue was performed since metabolic syndrome including obesity is highly associated with non-alcoholic fatty liver disease (NAFLD)⁴⁵. The high-fat diet had led to NAFLD-like manifestations in the liver tissue as expected (Figure 1E, Figure S3), however, the mice treated with untreated fecal virome (FVT-UnT) had a significantly decrease in their NAFLD activity score. The fluorescence-activated cell sorting (FACS) analysis performed in this study provided valuable insights into the immune cell composition of the fat tissue of the mice in different FVT treatment groups. The FVT-UnT treated mice showed a decrease in the number of central memory T cells CD8 (CD44+CD62I/CD8), dendritic cells (CD11c+/CD45), and M1 macrophages (CD11c+/F4.80) compared with the HFD-control mice. A reduction in adipose tissue macrophages is correlated with a decrease in adipose tissue inflammation and a reduction in insulin resistance that is induced by obesity⁴⁶⁻⁴⁸. Additionally, dendritic cells can play a role in the immune

response to liver injury⁴⁹. These findings suggest that FVT-UnT may have a suppressive effect on the immune response in the fat tissue of the mice which might result in a reducing liver pathology. The FACS analysis showed that mice fed a high-fat diet, except FVT-UnT mice, had a significant increase in the level of M1 macrophages (CD11c+/F4.80), which is consistent with previous studies indicating that high-fat diets promote M1 macrophage infiltration and activation in adipose tissue, leading to low-grade inflammation and insulin resistance⁵⁰.

Motivated by the observed effects of the FVT-ChP and FVT-UnT treatments on, respectively, the OGTT and histology measures, the cytokine profile of the mouse blood serum was examined since low grade systemic inflammation is connected to metabolic syndrome^{51,52}. The overall blood cytokine profile of the FVT-UnT treated mice was not different from the HFD-control mice, hence, these data does not explain the improved liver pathology associated with FVT-UnT compared to the HFD-control mice. In contrast, the cytokine profile of the FVT-ChP treated mice had significantly higher ($p < 0.005$) expression of several pro-inflammatory cytokines, such as IL-15, TNF- α , and MIP-2, than those of FVT-UnT, HFD-control, and LFD-control mice (Figure S7). TNF- α is produced by adipose tissue and work as pro-inflammatory cytokines that can contribute to insulin resistance and have been shown to play a role in the development of NAFLD^{53–55}. In obese individuals without type-2-diabetes, a study demonstrated that inhibiting TNF- α for a duration of 6 months resulted in a reduction in fasting glucose levels⁵⁵. The recruitment and activation of neutrophils via MIP-2 can prompt the release of diverse inflammatory mediators, which can hasten the onset of liver inflammation⁵⁶. The increased level of several pro-inflammatory cytokines of the FVT-ChP treated mice compared to the HFD-control may be related to the pathological liver score. How and if the blood cytokine profile of the FVT-ChP treated mice was linked to the improved blood glucose regulation (Figure 1D) is unknown.

The high-fat diet decreased ($p < 0.05$) the bacterial diversity and changed the bacterial composition of the mice compared to the low-fat diet, as expected^{22,57}. The FVT strongly influenced both the bacterial and viral GM composition (Table S1 & Table S2), with HFD-control mice being significantly ($p < 0.05$) different from both the FVT-UnT and FVT-ChP treated mice. The dominant bacterial phylum detected in the feces of mice were *Firmicutes*, *Bacteroidetes*, *Actinobacteria*, *Proteobacteria*, *Deferribacteres* and *Verrucomicrobia* (Figure S8). Our findings (Figure S9) revealed a significantly higher abundance of *Lactobacillus* in the gut of FVT-ChP mice compared to FVT-UnT ($p = 0.00295$), HFD-control ($p = 0.015762$), and LFD-control ($p = 0.000358$) mice. A decrease in the *Bacteroidetes/Firmicutes* ratio has been associated with improved metabolic health and lowered inflammation in several animal models and human studies^{58–60}, while increased levels of *Lactobacillus* in patients with non-alcoholic fatty liver disease (NAFLD) have been reported^{61–63}. A

high relative abundance of the *Lactobacillus* taxa may partly explain the increased pro-inflammatory response and symptoms of NAFLD that was associated with the FVT-ChP treated mice (Figure 1E and Figure S7). A significant increase ($p < 0.05$) in the relative abundance of *Allobaculum* was detected in feces samples from the FVT-ChP treated mice compared to HFD-control ($p = 0.04715$) and FVT-UnT mice ($p = 0.00358$), and it was not different ($p = 0.17821$) from the relative abundance of *Allobaculum* associated with LFD-control mice (Figure S9). *Allobaculum* is a Gram-negative bacteria found in both murine and human hosts^{64,65}. *Allobaculum* have been suggested to be an important gut bacterium that is inversely associated with high-fat diet induced metabolic syndrome including improved insulin response^{66–68}, which is in line with our observations of improved blood glucose regulation in the FVT-ChP treated mice. Differences in etiologies may explain our findings of better glucose control and reduced NAFLD in, respectively, FVT-ChP and FVT-UnT treated mice. Analysis of the differential abundance of both the viral contigs (vOTUs) and their predicted bacterial hosts showed clear differences when comparing the FVT-ChP with the FVT-UnT treatment (Figure S5 and Figure S6), hence, these differences in viral profiles may have contributed to the two different phenotypes.

Although the chemostat propagated virome (FVT-ChP) treatment promoted an inflammatory response measured in the blood serum, the FVT-ChP also showed the ability to reshape the gut microbiome composition and to improve the blood glucose regulation of the mice, likely through a cascade of events¹⁶. This emphasized the potential application of phage-mediated modulation of the gut microbiome to change the host phenotype.

FMT and FVT have the potential to revolutionize treatments for numerous gut-related diseases, but due to their inherent safety issues, widespread use is unlikely. Here we showed the potential of using chemostat propagated enteric viromes to improve safety of phage-mediated gut microbiome modulation that affects the host phenotype. When optimized in future studies, this approach has the potential for higher reproducibility, standardization, large-scale production, increased removal of eukaryotic viruses by further dilution, and depends on only a few effective donors.

Methods

The animal origin and preparation of donor viromes and FMT

In total 54 C57BL/6N male mice were purchased to harvest intestinal content for preparing FVT, as earlier described^{28,29}. In brief, the mice were five weeks old at arrival and purchased from three vendors, represented by 18 C57BL/6NTac mice (Taconic, Denmark), 18 C57BL/6NRj mice (Janvier, France), and 18 C57BL/6NCrl mice (Charles River, Germany). Animal housing was carried out at Section of Experimental Animal Models, University of Copenhagen, Denmark, under conditions as

described previously³⁹. For 13 weeks the mice were fed ad libitum low-fat diet (LF, Research Diets D12450J) until termination as 18 weeks old. To preserve the strict anaerobic bacteria for chemostat fermentation, 6 mice from each vendor (in total 18 mice) were sacrificed and immediately sampled for intestinal content under anoxic conditions. The intestinal content from the remaining mice was sampled in aerobic atmosphere to generate the fecal virome for downstream applications of the FVT-UnT, FVT-SDT, and FVT-PyT treatments. The abovementioned processes are illustrated with a flow-diagram (Figure S10). All procedures for handling of animals used for donor material were carried out in accordance with the Directive 2010/63/EU and the Danish Animal Experimentation Act with the license ID: 2012-15-2934-00256.

Untreated fecal virome (FVT-UnT)

Intestinal content from cecum and colon was thawed and processed to produce FVT solutions as previously described²², with the exception of using Centriprep Ultracel YM-30K units (Millipore) instead of YM-50K units for concentrating filtrates and removing metabolites below the size of 30 kDa. These fecal viromes were mixed into one mixture from mice of all three vendors representing the “untreated fecal virome”, FVT-UnT, which was immediately stored at -80°C. The remaining fecal viromes were further processed to inactivate the eukaryotic viruses in the fecal viromes by either dissolving the lipid membrane of enveloped viruses with solvent/detergent (S/D) treatment or inhibit replication of RNA viruses with pyronin Y treatment.

Solvent/detergent treated fecal virome (FVT-SDT)

The solvent/detergent (S/D) treatment is commonly used for inactivating enveloped viruses (most eukaryotic viruses are enveloped) in blood plasma, while non-enveloped viruses (most phages are non-enveloped) are not inactivated^{34,69,70}. The fecal viromes were treated by following the recommendations from the World Health Organization (WHO) for clinical use of S/D treated plasma; incubation in 1% (w/v) tri(n-butyl) phosphate (TnBP) and 1% (w/v) Triton X-100 at 30°C for 4 hours⁷¹. S/D treatment was performed by following the method of Horowitz *et al*³⁴ and the removal of TnBP and Triton X-100 were performed as described by Treščec *et al*.⁷². The removal of the S/D agents from the fecal viromes yielded approx. 100 mL viral-flow-through from the column which was concentrated to 0.5 mL using Centriprep Ultracel YM-30K units. The final product constituted the FVT-SDT treatment.

Pyronin Y treated fecal virome (FVT-PYT)

Pyronin Y (Merck) is a fluorescent compound (strong red-colored dye) that has been reported to efficiently bind to ss/dsRNA, while the binding to ss/dsDNA is less efficient^{35,36}. Fecal filtrate was treated with 100 µM pyronin Y and incubated at 40°C overnight to inactivate viral particles containing RNA genomes. The non-bound pyronin Y molecules were removed by diluting the pyronin y treated

fecal filtrate suspensions in 50 mL SM-buffer followed by concentration to 0.5 mL with Centriprep Ultracel YM-30K units. This process was repeated three times and resulted in an almost transparent appearance of the pyronin Y-treated fecal filtrate, which constituted the FVT-PyT treatment.

Chemostat propagated fecal virome (FVT-ChP)

The preparation of the chemostat propagated virome was performed as described previously²⁹. In brief, anaerobic-handled mouse cecum content was used for chemostat propagation. The culture medium was designed to mimic the LF diet (Research Diets D12450J) that the donor mice were provided as feed and the growth conditions as temperature, pH, etc. were set to mimic the environmental conditions found in mouse cecum. The end cultures fermented with a slow dilution rate (0.05 volumes 1/h) showed to generate a microbial composition closest to the donor's initial microbial composition profile²⁹, and these batches were mixed and constituted the applied FVT-ChP treatment.

Fluorescence microscopy

Virus-like particle (VLP) counts were evaluated of all applied fecal viromes (FVT-UnT, FVT-SdT, FVT-ChP, and FVT-PyT) by epifluorescence microscopy stained by SYBRTM Gold (Thermo Scientific, cat. no. S11494) as described [dx.doi.org/10.17504/protocols.io.bx6cpraw](https://doi.org/10.17504/protocols.io.bx6cpraw). The viral concentration was normalized to 2 x 10⁹ VLP/mL per treatment.

Animal model design

Forty-eight male C57BL/6NTac mice (Taconic Biosciences A/S, Lille Skensved, Denmark) were divided into 6 groups at 5 weeks of age: low-fat diet (LFD, as lean control), high-fat diet (HFD, as obese and prediabetic control), FVT-UnT (as control for modified FVTs), FVT-ChP, FVT-SdT, and FVT-PyT (Figure 5). Only male C57BL/6NTac mice were included since female mice are protected against DIO⁷³. For 18 weeks, mice were fed ad libitum a HFD (Research Diets D12492, USA), except the LFD control mice that was fed a LFD (Research Diets D12450J, USA). After 6 whole weeks on their respective diets, the FVT-UnT, FVT-ChP, FVT-SdT, and FVT-PyT mice were treated twice by FVT with 0.15 mL enteric virome by oral gavage with a 1-week interval (study weeks 7 and 8) between the FVTs. The titre of the applied FVT virome was approximately 2 × 10⁹ virus-like particles (VLP)/mL (Figure S11). The mice were subjected to an oral glucose tolerance test (OGTT) at week 13 and 18 of the study, and food intake and mouse weight were monitored frequently. Procedures were carried out in accordance with the Directive 2010/63/EU and the Danish law LBK Nr 726 af 09/091993, and housing conditions as earlier described³⁹. Blood serum, epididymal white adipose tissue (eWAT), mesenteric lymph node (MLN), liver tissue, intestinal content from the cecum and colon, as well as tissue from the colon and ileum were sampled at termination at study week 18 (23 weeks old) and stored at -80°C until downstream analysis. Liver tissue was fixated in 10% neutral-

buffered formalin (Sarstedt Formalin System) for histological analysis and stored at room temperature. All procedures regarding the handling of these animals were carried out in accordance with the Directive 2010/63/EU and the Danish Animal Experimentation Act with the license ID: 2017-15-0201-01262 C1.

Cytokine analysis

Pre-weighted tissue was homogenized in 400µl lysis buffer (stock solution: 10ml Tris lysis buffer, 100µl phosphatase inhibitor 1, 100µl phosphatase inhibitor 2, and 200µl protease inhibitor (MSD inhibitor pack, Mesoscale Discovery, Rockville, MD) using a tissue blender (POLYTRON PT 1200 E, Kinematica, Luzern, Switzerland), and centrifuged (7,500g; 4°C; 5 min). Samples were diluted 1:2 and analyzed for IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12p70, KC/GRO, and TNF-α with V-PLEX Proinflammatory Panel 1 Mouse kit (Mesoscale Discovery) and for MIP-3α, IL-16, IL-17A, IL-17C, IL-17E, IL-17F, IL-21, IL-22, IL-23, and IL-31 with V-PLEX Th17 Panel 1 Mouse (Mesoscale Discovery) according to manufacturer's instructions. Measurements out of detection range were assigned the value of lower or upper detection limit. Concentrations were extrapolated from a standard curve and normalized to total protein measured with Pierce Detergent Compatible Bradford Assay kit according to manufacturer's protocol.

Histology

Formalin-fixed liver biopsies were embedded in paraffin, sectioned and stained with hematoxylin & eosin for histopathological evaluation. We used a cumulative semi-quantitative NAFLD activity score (NAS) comprising the following three histological features: Steatosis (0-3), immune cell margination and infiltration (0-2), and hepatocellular ballooning (0-2) with higher values corresponding to increased dissemination. The histological assessment was performed by a blinded investigator.

Cell isolation and flow cytometry (FACS)

Directly after sacrificing the mice, the mesenteric lymph node and white adipose tissue (eWAT) were placed in ice cold PBS. Single cell suspensions were prepared by disrupting the lymph node between two microscope glasses and passing it through a 70 µm nylon mesh. After washing and resuspension, 1x10⁶ cells were surface stained for 30 min with antibodies for Percp-Cy5.5 conjugated CD11c, PE-conjugated CD86, APC-conjugated CD11b, and FITC-conjugated CD103 (all antibodies were purchased from eBiosciences) for the detection of tolerogenic dendritic cells (DCs). For the detection of T cell subsets, 1x10⁶ cells were initially surface stained for 30 min with FITC-conjugated CD3, PercP-Cy5.5-conjugated CD4, and APC-conjugated CD8a (ebiosciences), then fixate and permeabilized with the FoxP3/Transcription Factor Staining Buffer Set (ebiosciences), and finally stained for 30 min with PE-conjugated intracellular forkhead box P3 (FOXP3) (ebioscience). Analysis was performed using an Accuri C6 flow cytometer (Accuri Cytometers).

Pre-processing of fecal samples for separation of viruses and bacteria

Fecal samples from three different timepoints were included to investigate gut microbiome changes over time: arrival at our housing facility, 1 week after 2nd FVT, and at termination. This represented in total 144 fecal samples. Separation of the viruses and bacteria from the fecal samples generated a fecal pellet and fecal supernatant by centrifugation and 0.45 µm filtering as described previously³⁹, however, the volume of fecal homogenate was adjusted to 5 mL SM buffer.

Bacterial DNA extraction, sequencing and pre-processing of raw data

The DNeasy PowerSoil Pro Kit (Qiagen) was used to extract bacterial DNA from the fecal pellet by following the instructions of the manufacturer. The final purified DNA was stored at -80°C and the DNA concentration was determined using Qubit HS Assay Kit (Invitrogen, Carlsbad, California, USA) on the Qubit 4 Fluorometric Quantification device (Invitrogen, Carlsbad, California, USA). The bacterial community composition was determined by Illumina NextSeq-based high-throughput sequencing (HTS) of the 16S rRNA gene V3-region, as previously described³⁹. Quality-control of reads, de-replicating, purging from chimeric reads and constructing zOTU was conducted with the UNOISE pipeline⁷⁴ and taxonomically assigned with Sintax⁷⁵ (not yet peer reviewed). Taxonomical assignments were obtained using the EZtaxon for 16S rRNA gene database⁷⁶. Code describing this pipeline can be accessed in github.com/jcame/Fastq_2_zOTUtable. The average sequencing depth after quality control (Accession: PRJEB58786, available at ENA) for the fecal 16S rRNA gene amplicons was 67,454 reads (min. 12,790 reads and max. 295,746 reads).

Viral RNA/DNA extraction, sequencing and pre-processing of raw data

The sterile filtered fecal supernatant was concentrated using centrifugal filters Centrisart with a filter cut-off at 100 kDa (Sartorius) by centrifugation centrifuged at 1,500 x g at 4°C

([dx.doi.org/10.17504/protocols.io.b2qaqdse](https://doi.org/10.17504/protocols.io.b2qaqdse)). The viral DNA/RNA was extracted from the fecal supernatants with Viral RNA mini kit (Qiagen) as previously described³⁹. Reverse transcription was executed with SuperScript VILO Master mix by following the instructions of the manufacturer and subsequently cleaned with DNeasy blood and tissue kit (Qiagen) by only following step 3-8. In brief, the DNA/cDNA samples were mixed with ethanol, bound to the silica filter, washed two times, and eluted with 40 µL elution buffer. Multiple displacement amplification (MDA, to include ssDNA viruses) using GenomiPhi V3 DNA amplification kit (Cytiva) and sequencing library preparation using Nextera XT kit was performed as previously described³⁹, and sent for sequencing using the NovaSeq platform (NovoGene). The average sequencing depth of raw reads (Accession: PRJEB58786, available at ENA) for the fecal viral metagenome was 13,145,283 reads (min. 693,882 reads and max. 142,821,858 reads). The raw reads were trimmed from adaptors and the high-quality sequences (>95% quality) using Trimmomatic v0.35⁷⁷ with a minimum size of 50nt were retained for further analysis. High quality reads were de-replicated and checked for the presence of PhiX control using BBMap (bbduk.sh) (<https://www.osti.gov/servlets/purl/1241166>). Virus-like particle-derived DNA sequences were subjected to within-sample de-novo assembly-only using Spades v3.13.1⁷⁸ and the contigs with a minimum length of 2,200 nt, were retained. Contigs generated from all samples were pooled and de-replicated at 90% identity using BBMap (dedupe.sh). Prediction of viral contigs/genomes was carried out using VirSorter2⁷⁹ ("full" categories | dsDNAphage, ssDNA, RNA, Lavidaviridae, NCLDV | viralquality ≥ 0.66), vibrant⁸⁰ (High-quality | Complete), and checkv⁸¹ (High-quality | Complete). Taxonomy was inferred by blasting viral ORF against viral orthologous groups (<https://vogdb.org>) and the Lowest Common Ancestor (LCA) for every contig was estimated based on a minimum e-value of 10e⁻⁵. Phage-host prediction was determined by blasting (85% identity) CRISPR spacers and tRNAs predicted from >150,000 gut species-level genome bins (SGBs)^{82,83} (⁸³, not yet peer reviewed). Following assembly, quality control, and annotations, reads from all samples were mapped against the viral (high-quality) contigs (vOTUs) using the bowtie2⁸⁴ and a contingency-table of reads per Kbp of contig sequence per million reads sample (RPKM) was generated, here defined as vOTU-table (viral contigs). Code describing this pipeline can be accessed in github.com/jcame/virome_analysis-FOOD.

Bioinformatic analysis of bacterial and viral sequences

Initially the dataset was purged for zOTU's/viral contigs, which were detected in less than 5% of the samples, but the resulting dataset still maintained 99.5% of the total reads. Cumulative sum scaling (CSS)⁸⁵ was applied for the analysis of beta-diversity to counteract that a few zOTU/viral contigs represented a majority of count values, since CSS have been benchmarked with a high accuracy for the applied metrics⁸⁶. CSS normalization was performed using the R software using the

metagenomeSeq package⁸⁷. R version 4.2.2⁸⁸ was used for subsequent analysis and presentation of data. The main packages used were phyloseq⁸⁹, vegan⁹⁰, deseq2⁹¹, ampvis2⁹², ggpubr⁹³ and ggplot2⁹³. A-diversity analysis was based on raw read counts and statistics were based on ANOVA. B-diversity was represented by Bray Curtis dissimilarity and statistics were based on PERMANOVA. T-test with pooled standard deviations was applied to assess the statistically differences between the treatment groups of cytokine levels, immune cell levels, eWAT, bodyweight, and histology. Mouse data (weight and OGTT levels) were analyzed in GraphPad Prism using one-way analysis of variance with Tukey's post hoc test.

Acknowledgements

We thank the animal caretakers Helene Farlov and Mette Nelander at Section of Experimental Animal Models (University of Copenhagen, Denmark) for taking care of the animals during the study and assisting with the animal handling.

Funding

Funding was provided by the Lundbeck Foundation with grant ID: R324-2019-1880 under the acronym "SafeVir" and the Novo Nordisk Foundation with grant ID: NNF-20OC0063874 under the acronym "PrePhage".

Author contributions

TSR and DSN conceived the research idea and designed the study; TSR and SBL, performed the experiments; TSR, SBL, XM, LSFZ, AB, SA, JLCM, CHFH, KA, and AKH performed laboratory and data analysis; XM and TSR wrote the first draft of the manuscript. All authors critically revised and approved the final version of the manuscript.

Competing interests

All authors declare no conflicts of interest.

References

1. Kyrou, I.; Randeva, H.S.; Tsigos, C.; Kaltsas, G.; Weickert, M.O. Clinical Problems Caused by Obesity. In *Endotext*; Feingold, K.R., Anawalt, B., Boyce, A., Chrousos, G., de Herder, W.W., Dhatariya, K., Dungan, K., Hershman, J.M., Hofland, J., Kalra, S., et al. World Health Organization. World Obesity Day 2022—Accelerating Action to Stop Obesity. 2022;
2. Leitner DR, Frühbeck G, Yumuk V, Schindler K, Micic D, Woodward E, Toplak H. Obesity and Type 2 Diabetes: Two Diseases with a Need for Combined Treatment Strategies - EASO Can Lead the Way. *Obes Facts* 2017; 10:483–92.
3. Yumuk V, Tsigos C, Fried M, Schindler K, Busetto L, Micic D, Toplak H, Obesity Management Task Force of the European Association for the Study of Obesity. European Guidelines for Obesity Management in Adults. *Obes Facts* 2015; 8:402–24.
4. Blomain ES, Dirhan DA, Valentino MA, Kim GW, Waldman SA. Mechanisms of Weight Regain following Weight Loss. *ISRN Obes* 2013; 2013:1–7.
5. Maruvada P, Leone V, Kaplan LM, Chang EB. The Human Microbiome and Obesity: Moving beyond Associations. *Cell Host Microbe* 2017; 22:589–99.
6. Bäckhed F, Manchester JK, Semenkovich CF, Gordon JL. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. *Proc Natl Acad Sci U S A* 2007; 104:979–84.
7. Thaïss CA, Itav S, Rothschild D, Meijer MT, Levy M, Moresi C, Dohnalová L, Braverman S, Rozin S, Malitsky S, et al. Persistent microbiome alterations modulate the rate of post-dieting weight regain. *Nature [Internet]* 2016; 540:544–51. Available from: <http://www.nature.com/articles/nature20796>
8. Ridaura VK, Faith JJ, Rey FE, Cheng J, Duncan AE, Kau AL, Griffin NW, Lombard V, Henrissat B, Bain JR, et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. *Science* 2013; 341:1241214.
9. Lahtinen P, Juuti A, Luostarinen M, Niskanen L, Liukkonen T, Tillonen J, Kössi J, Ilvesmäki V, Viljakka M, Satokari R, et al. Effectiveness of Fecal Microbiota Transplantation for Weight Loss in Patients With Obesity Undergoing Bariatric Surgery. *JAMA Netw Open* 2022; 5:e2247226.
10. Allegretti JR, Kassam Z, Mullish BH, Chiang A, Carrellas M, Hurtado J, Marchesi JR, McDonald JAK, Pechlivanis A, Barker GF, et al. Effects of Fecal Microbiota Transplantation With Oral Capsules in Obese Patients. *Clin Gastroenterol Hepatol* 2020; 18:855-863.e2.
11. Yu EW, Gao L, Stastka P, Cheney MC, Mahabamunuge J, Soto MT, Ford CB, Bryant JA, Henn MR, Hohmann EL. Fecal microbiota transplantation for the improvement of metabolism in obesity: The FMT-TRIM double-blind placebo-controlled pilot trial. *PLoS Med* 2020; 17.
12. Wang J-W, Kuo C-H, Kuo F-C, Wang Y-K, Hsu W-H, Yu F-J, Hu H-M, Hsu P-I, Wang J-Y, Wu D-C. Fecal microbiota transplantation: Review and update. *Journal of the Formosan Medical Association* 2019; 118:S23–31.
13. FDA. Important safety alert regarding use of FMT [Internet]. 2019 [cited 2019 Jul 4]; Available from: <https://www.fda.gov/vaccines-blood-biologics/safety-availability->

503 biologics/important-safety-alert-regarding-use-fecal-microbiota-transplantation-and-risk-
504 serious-adverse

505 14. Marotz CA, Zarrinpar A. Treating Obesity and Metabolic Syndrome with Fecal Microbiota
506 Transplantation. *Yale J Biol Med* 2016; 89:383–8.

507 15. Ross A, Ward S, Hyman P. More Is Better: Selecting for Broad Host Range Bacteriophages.
508 *Front Microbiol* 2016; 7:1–6.

509 16. Rasmussen TS, Koefoed AK, Jakobsen RR, Deng L, Castro-Mejía JL, Brunse A, Neve H,
510 Vogensen FK, Nielsen DS. Bacteriophage-mediated manipulation of the gut microbiome -
511 promises and presents limitations. *FEMS Microbiol Rev* 2020; 44:507–21.

512 17. Lim ES, Zhou Y, Zhao G, Bauer IK, Droit L, Ndao IM, Warner BB, Tarr PI, Wang D, Holtz
513 LR. Early life dynamics of the human gut virome and bacterial microbiome in infants. *Nat*
514 *Med* 2015; 21:1228–34.

515 18. Liang G, Zhao C, Zhang H, Mattei L, Sherrill-Mix S, Bittinger K, Kessler LR, Wu GD,
516 Baldassano RN, DeRusso P, et al. The stepwise assembly of the neonatal virome is
517 modulated by breastfeeding. *Nature* 2020; 581:470–4.

518 19. Wu D, Zhang C, Liu Y, Yao J, Yang X, Wu S, Du J, Yang X, Wu D, Zhang C, et al. Beyond
519 faecal microbiota transplantation, the non-negligible role of faecal virome or bacteriophage
520 transplantation. *Journal of Microbiology, Immunology and Infection* [Internet] 2023 [cited
521 2023 Mar 10]; Available from: <http://creativecommons.org/licenses/by-nc-nd/4.0/>

522 20. Kao DH, Roach B, Walter J, Lobenberg R, Wong K. Effect of lyophilized sterile fecal filtrate
523 vs lyophilized donor stool on recurrent *Clostridium difficile* infection (rCDI): Preliminary
524 results from a randomized, double-blind pilot study. *J Can Assoc Gastroenterol* 2019;
525 2:101–2.

526 21. Ott SJ, Waetzig GH, Rehman A, Moltzau-Anderson J, Bharti R, Grasis JA, Cassidy L,
527 Tholey A, Fickenscher H, Seegert D, et al. Efficacy of Sterile Fecal Filtrate Transfer for
528 Treating Patients With *Clostridium difficile* Infection. *Gastroenterology* 2017; 152:799-
529 811.e7.

530 22. Rasmussen TS, Mentzel CMJ, Kot W, Castro-Mejía JL, Zuffa S, Swann JR, Hansen LH,
531 Vogensen FK, Hansen AK, Nielsen DS. Faecal virome transplantation decreases symptoms
532 of type 2 diabetes and obesity in a murine model. *Gut* [Internet] 2020 [cited 2020 Mar 13];
533 69:2122–30. Available from: <https://doi.org/10.1136/gutjnl-2019-320005>

534 23. Brunse A, Deng L, Pan X, Hui Y, Castro-Mejía JL, Kot W, Nguyen DN, Secher JB-M,
535 Nielsen DS, Thymann T. Fecal filtrate transplantation protects against necrotizing
536 enterocolitis. *ISME J* 2022; 16:686–94.

537 24. Draper LA, Ryan FJ, Dalmasso M, Casey PG, McCann A, Velayudhan V, Ross RP, Hill C.
538 Autochthonous faecal viral transfer (FVT) impacts the murine microbiome after antibiotic
539 perturbation. *BMC Biol* 2020; 18:173.

540 25. Cao Z, Sugimura N, Burgermeister E, Ebert MP, Zuo T, Lan P. The gut virome: A new
541 microbiome component in health and disease. *EBioMedicine* 2022; 81:104113.

- 542 26. Shah SA, Deng L, Thorsen J, Pedersen AG, Dion MB, Castro-Mejía JL, Silins R, Romme
543 FO, Sausset R, Ndela EO, et al. Hundreds of viral families in the healthy infant gut. *bioRxiv*
544 2022;
- 545 27. Doorbar J, Egawa N, Griffin H, Kranjec C, Murakami I. Human papillomavirus molecular
546 biology and disease association. *Rev Med Virol* 2015; 25:2–23.
- 547 28. Rasmussen TS, Forster S, Larsen SB, Von Münchow A, Tranæs KD, Brunse A, Castro-
548 Mejia JL, Adamberg S, Hansen AK, Adamberg K, et al. Development of safe and effective
549 bacteriophage-mediated therapies against *C. difficile* infections – a proof-of-concept
550 preclinical study . *bioRxiv* 2023;
- 551 29. Adamberg S, Rasmussen TS, Larsen SB, Nielsen DS, Adamberg K. Reproducible
552 chemostat cultures to eliminate eukaryotic viruses from fecal transplant material. *bioRxiv*
553 2023;
- 554 30. Rey FA, Lok S-M. Common Features of Enveloped Viruses and Implications for Immunogen
555 Design for Next-Generation Vaccines. *Cell* 2018; 172:1319–34.
- 556 31. Bell PJL. Evidence supporting a viral origin of the eukaryotic nucleus. *Virus Res* 2020;
557 289:198168.
- 558 32. Koonin E V., Dolja V V., Krupovic M. Origins and evolution of viruses of eukaryotes: The
559 ultimate modularity. *Virology* 2015; 479–480:2–25.
- 560 33. Sausset R, Petit MA, Gaboriau-Routhiau V, De Paepe M. New insights into intestinal
561 phages. *Mucosal Immunol* 2020; 13:205–15.
- 562 34. Horowitz B, Bonomo R, Prince AM, Chin SN, Brotman B, Shulman RW. Solvent/detergent-
563 treated plasma: a virus-inactivated substitute for fresh frozen plasma. *Blood* 1992; 79:826–
564 31.
- 565 35. Kapuscinski J, Darzynkiewicz Z. Interactions of pyronin Y(G) with nucleic acids. *Cytometry*
566 1987; 8:129–37.
- 567 36. Darzynkiewicz Z, Kapuscinski J, Carter SP, Schmid FA, Melamed MR. Cytostatic and
568 cytotoxic properties of pyronin Y: relation to mitochondrial localization of the dye and its
569 interaction with RNA. *Cancer Res* 1986; 46:5760–6.
- 570 37. Rao K, Erb-Downward JR, Walk ST, Micic D, Falkowski N, Santhosh K, Mogle JA, Ring C,
571 Young VB, Huffnagle GB, et al. The Systemic Inflammatory Response to *Clostridium difficile*
572 Infection. *PLoS One* 2014; 9:e92578.
- 573 38. Fraulob JC, Ogg-Diamantino R, Fernandes-Santos C, Aguila MB, Mandarin-de-Lacerda
574 CA. A Mouse Model of Metabolic Syndrome: Insulin Resistance, Fatty Liver and Non-
575 Alcoholic Fatty Pancreas Disease (NAFPD) in C57BL/6 Mice Fed a High Fat Diet. *J Clin*
576 *Biochem Nutr* 2010; 46:212–23.
- 577 39. Rasmussen TS, de Vries L, Kot W, Hansen LH, Castro-Mejía JL, Vogensen FK, Hansen AK,
578 Nielsen DS. Mouse Vendor Influence on the Bacterial and Viral Gut Composition Exceeds
579 the Effect of Diet. *Viruses* 2019; 11.
- 580 40. Ericsson AC, Davis JW, Spollen W, Bivens N, Givan S, Hagan CE, McIntosh M, Franklin
581 CL. Effects of vendor and genetic background on the composition of the fecal microbiota of
582 inbred mice. *PLoS One* 2015; 10:1–19.

- 583 41. Lundberg R, Bahl MI, Licht TR, Toft MF, Hansen AK. Microbiota composition of
584 simultaneously colonized mice housed under either a gnotobiotic isolator or individually
585 ventilated cage regime. *Sci Rep* 2017; 7:1–11.
- 586 42. Rasmussen TS, Jakobsen RR, Castro-Mejía JL, Kot W, Thomsen AR, Vogensen FK,
587 Nielsen DS, Hansen AK. Inter-vendor variance of enteric eukaryotic DNA viruses in specific
588 pathogen free C57BL/6N mice. *Res Vet Sci* 2021; 136:1–5.
- 589 43. Raghupathi W, Raghupathi V. An Empirical Study of Chronic Diseases in the United States:
590 A Visual Analytics Approach to Public Health. *Int J Environ Res Public Health* [Internet] 2018
591 [cited 2023 Mar 10]; 15. Available from: /pmc/articles/PMC5876976/
- 592 44. Reynolds R, Dennis S, Hasan I, Slewa J, Chen W, Tian D, Bobba S, Zwar N. A systematic
593 review of chronic disease management interventions in primary care. *BMC Fam Pract*
594 [Internet] 2018 [cited 2023 Mar 10]; 19. Available from: /pmc/articles/PMC5759778/
- 595 45. Powell EE, Wong VWS, Rinella M. Non-alcoholic fatty liver disease. *The Lancet* 2021;
596 397:2212–24.
- 597 46. Nomiyama T, Perez-Tilve D, Ogawa D, Gizard F, Zhao Y, Heywood EB, Jones KL,
598 Kawamori R, Cassis LA, Tschöp MH, et al. Osteopontin mediates obesity-induced adipose
599 tissue macrophage infiltration and insulin resistance in mice. *J Clin Invest* 2007; 117:2877.
- 600 47. Lesniewski LA, Hosch SE, Neels JG, De Luca C, Pashmforoush M, Lumeng CN, Chiang
601 SH, Scadeng M, Saltiel AR, Olefsky JM. Bone marrow–specific Cap gene deletion protects
602 against high-fat diet–induced insulin resistance. *Nature Medicine* 2007 13:4 2007; 13:455–
603 62.
- 604 48. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW. Obesity is
605 associated with macrophage accumulation in adipose tissue. *J Clin Invest* [Internet] 2003
606 [cited 2023 Mar 10]; 112:1796–808. Available from: <http://www.insightful>.
- 607 49. Sutti S, Locatelli I, Bruzzì S, Jindal A, Vacchiano M, Bozzola C, Albano E. CX3CR1-
608 expressing inflammatory dendritic cells contribute to the progression of steatohepatitis. *Clin*
609 *Sci* 2015; 129:797–808.
- 610 50. Fujisaka S. The role of adipose tissue M1/M2 macrophages in type 2 diabetes mellitus.
611 *Diabetol Int* [Internet] 2020 [cited 2023 Mar 10]; 12:74–9. Available from:
612 <https://pubmed.ncbi.nlm.nih.gov/33479582/>
- 613 51. Guarner V, Rubio-Ruiz ME. Low-Grade Systemic Inflammation Connects Aging, Metabolic
614 Syndrome and Cardiovascular Disease. *Interdiscip Top Gerontol* 2015; 40:99–106.
- 615 52. Mansyur MA, Bakri S, Patellongi IJ, Rahman IA. The association between metabolic
616 syndrome components, low-grade systemic inflammation and insulin resistance in non-
617 diabetic Indonesian adolescent male. *Clin Nutr ESPEN* 2020; 35:69–74.
- 618 53. Tangvarasittichai S, Pongthaisong S, Tangvarasittichai O. Tumor Necrosis Factor-A,
619 Interleukin-6, C-Reactive Protein Levels and Insulin Resistance Associated with Type 2
620 Diabetes in Abdominal Obesity Women. *Indian J Clin Biochem* 2016; 31:68–74.
- 621 54. Kakino S, Ohki T, Nakayama H, Yuan X, Otabe S, Hashinaga T, Wada N, Kurita Y, Tanaka
622 K, Hara K, et al. Pivotal Role of TNF- α in the Development and Progression of Nonalcoholic
623 Fatty Liver Disease in a Murine Model. *Hormone and Metabolic Research* 2018; 50:80–7.

- 624 55. Stanley TL, Zanni M V., Johnsen S, Rasheed S, Makimura H, Lee H, Khor VK, Ahima RS,
625 Grinspoon SK. TNF- α Antagonism with Etanercept Decreases Glucose and Increases the
626 Proportion of High Molecular Weight Adiponectin in Obese Subjects with Features of the
627 Metabolic Syndrome. *J Clin Endocrinol Metab* 2011; 96:E146–50.
- 628 56. Qin CC, Liu YN, Hu Y, Yang Y, Chen Z. Macrophage inflammatory protein-2 as mediator of
629 inflammation in acute liver injury. *World J Gastroenterol* 2017; 23:3043–52.
- 630 57. Sun L, Ma L, Ma Y, Zhang F, Zhao C, Nie Y. Insights into the role of gut microbiota in
631 obesity: pathogenesis, mechanisms, and therapeutic perspectives. *Protein Cell* 2018;
632 9:397–403.
- 633 58. Armougom F, Henry M, Vialettes B, Raccach D, Raoult D. Monitoring Bacterial Community of
634 Human Gut Microbiota Reveals an Increase in *Lactobacillus* in Obese Patients and
635 Methanogens in Anorexic Patients. *PLoS One* 2009; 4:e7125.
- 636 59. Xu P, Li M, Zhang J, Zhang T. Correlation of intestinal microbiota with overweight and
637 obesity in Kazakh school children. *BMC Microbiol* 2012; 12:283.
- 638 60. Bervoets L, Van Hoorenbeeck K, Kortleven I, Van Noten C, Hens N, Vael C, Goossens H,
639 Desager KN, Vankerckhoven V. Differences in gut microbiota composition between obese
640 and lean children: a cross-sectional study. *Gut Pathog* 2013; 5:10.
- 641 61. Duarte SMB, Stefano JT, Miele L, Ponziani FR, Souza-Basqueira M, Okada LSRR, de
642 Barros Costa FG, Toda K, Mazo DFC, Sabino EC, et al. Gut microbiome composition in lean
643 patients with NASH is associated with liver damage independent of caloric intake: A
644 prospective pilot study. *Nutrition, Metabolism and Cardiovascular Diseases* 2018; 28:369–
645 84.
- 646 62. Raman M, Ahmed I, Gillevet PM, Probert CS, Ratcliffe NM, Smith S, Greenwood R,
647 Sikaroodi M, Lam V, Crotty P, et al. Fecal microbiome and volatile organic compound
648 metabolome in obese humans with nonalcoholic fatty liver disease. *Clinical*
649 *Gastroenterology and Hepatology* 2013; 11:868-875.e3.
- 650 63. Da Silva HE, Teterina A, Comelli EM, Taibi A, Arendt BM, Fischer SE, Lou W, Allard JP.
651 Nonalcoholic fatty liver disease is associated with dysbiosis independent of body mass
652 index and insulin resistance. *Scientific Reports* 2018 8:1 2018; 8:1–12.
- 653 64. Guo WL, Chen M, Pan WL, Zhang Q, Xu JX, Lin YC, Li L, Liu B, Bai WD, Zhang YY, et al.
654 Hypoglycemic and hypolipidemic mechanism of organic chromium derived from chelation of
655 *Grifola frondosa* polysaccharide-chromium (III) and its modulation of intestinal microflora in
656 high fat-diet and STZ-induced diabetic mice. *Int J Biol Macromol* 2020; 145:1208–18.
- 657 65. van Muijlwijk GH, van Mierlo G, Jansen PWTC, Vermeulen M, Bleumink-Pluym NMC, Palm
658 NW, van Putten JPM, de Zoete MR. Identification of *Allobaculum mucolyticum* as a novel
659 human intestinal mucin degrader. *Gut Microbes* 2021; 13.
- 660 66. Cox LM, Yamanishi S, Sohn J, Alekseyenko A V., Leung JM, Cho I, Kim SG, Li H, Gao Z,
661 Mahana D, et al. Altering the Intestinal Microbiota during a Critical Developmental Window
662 Has Lasting Metabolic Consequences. *Cell* 2014; 158:705–21.
- 663 67. Zhang X, Zhao Y, Zhang M, Pang X, Xu J, Kang C, Li M, Zhang C, Zhang Z, Zhang Y, et al.
664 Structural Changes of Gut Microbiota during Berberine-Mediated Prevention of Obesity and
665 Insulin Resistance in High-Fat Diet-Fed Rats. *PLoS One* [Internet] 2012 [cited 2023 Mar 10];

- 666 7:e42529. Available from:
667 <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0042529>
- 668 68. Scheithauer TPM, Rampanelli E, Nieuwdorp M, Vallance BA, Verchere CB, van Raalte DH,
669 Herrema H. Gut Microbiota as a Trigger for Metabolic Inflammation in Obesity and Type 2
670 Diabetes. *Front Immunol* [Internet] 2020 [cited 2023 Mar 10]; 11:571731. Available from:
671 [/pmc/articles/PMC7596417/](https://pubmed.ncbi.nlm.nih.gov/3256417/)
- 672 69. Prince AM, Horowitz B, Brotman B. Sterilisation of hepatitis and HTLV-III viruses by
673 exposure to tri(n-butyl)phosphate and sodium cholate. *Lancet* 1986; 1:706–10.
- 674 70. Remy MM, Alfter M, Chiem M-N, Barbani MT, Engler OB, Suter-Riniker F. Effective
675 chemical virus inactivation of patient serum compatible with accurate serodiagnosis of
676 infections. *Clin Microbiol Infect* 2019; 25:907.e7-907.e12.
- 677 71. WHO Health Product Policy and Standards Team. Guidelines on viral inactivation and
678 removal procedures intended to assure the viral safety of human blood plasma products
679 [Internet]. 2004 [cited 2023 Jan 2]; :WHO-TRS924-Annex4-1-82. Available from:
680 <https://www.who.int/publications/m/item/WHO-TRS924-Annex4>
- 681 72. Trescec A, Simić M, Branović K, Gebauer B, Benko B. Removal of detergent and solvent
682 from solvent-detergent-treated immunoglobulins. *J Chromatogr A* 1999; 852:87–91.
- 683 73. Pettersson US, Waldén TB, Carlsson PO, Jansson L, Phillipson M. Female Mice are
684 Protected against High-Fat Diet Induced Metabolic Syndrome and Increase the Regulatory
685 T Cell Population in Adipose Tissue. *PLoS One* 2012; 7.
- 686 74. Edgar RC. Updating the 97% identity threshold for 16S ribosomal RNA OTUs.
687 *Bioinformatics* 2018; 34:2371–5.
- 688 75. Edgar R. SINTAX: a simple non-Bayesian taxonomy classifier for 16S and ITS sequences.
689 *bioRxiv* [Internet] 2016 [cited 2018 Jun 5]; :074161. Available from:
690 <https://doi.org/10.1101/074161>
- 691 76. Kim O-S, Cho Y-J, Lee K, Yoon S-H, Kim M, Na H, Park S-C, Jeon YS, Lee J-H, Yi H, et al.
692 Introducing EzTaxon-e: a prokaryotic 16S rRNA gene sequence database with phylotypes
693 that represent uncultured species. *Int J Syst Evol Microbiol* 2012; 62:716–21.
- 694 77. Bolger AM, Lohse M, Usadel B. Trimmomatic: A flexible trimmer for Illumina sequence data.
695 *Bioinformatics* 2014; 30:2114–20.
- 696 78. Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, Lesin VM, Nikolenko
697 SI, Pham S, Prjibelski AD, et al. SPAdes: a new genome assembly algorithm and its
698 applications to single-cell sequencing. *Journal of Computational Biology* 2012; 19:455–77.
- 699 79. Guo J, Bolduc B, Zayed AA, Varsani A, Dominguez-Huerta G, Delmont TO, Pratama AA,
700 Gazitúa MC, Vik D, Sullivan MB, et al. VirSorter2: a multi-classifier, expert-guided approach
701 to detect diverse DNA and RNA viruses. *Microbiome* 2021; 9:37.
- 702 80. Kieft K, Zhou Z, Anantharaman K. VIBRANT: automated recovery, annotation and curation
703 of microbial viruses, and evaluation of viral community function from genomic sequences.
704 *Microbiome* 2020; 8:90.

- 705 81. Nayfach S, Camargo AP, Schulz F, Elie-Fadrosh E, Roux S, Kyrpides NC. CheckV
706 assesses the quality and completeness of metagenome-assembled viral genomes. Nat
707 Biotechnol 2021; 39:578–85.
- 708 82. Pasolli E, Asnicar F, Manara S, Zolfo M, Karcher N, Armanini F, Beghini F, Manghi P, Tett
709 A, Ghensi P, et al. Extensive unexplored human microbiome diversity revealed by over
710 150,000 genomes from metagenomes spanning age, geography, and lifestyle. Cell 2019;
711 176:649-662.e20.
- 712 83. Castro-Mejía JL, Khakimov B, Lind M V, Garne E, Paulová P, Tavakkoli E, Hansen LH,
713 Smilde AK, Holm L, Engelsen SB, et al. Gut microbiome and its cofactors are linked to
714 lipoprotein distribution profiles. bioRxiv 2021; :2021.09.01.458531.
- 715 84. Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat Methods 2012;
716 9:357–9.
- 717 85. Paulson JN, Stine OC, Bravo HC, Pop M. Differential abundance analysis for microbial
718 marker-gene surveys. Nat Methods 2013; 10:1200–2.
- 719 86. Weiss S, Xu ZZ, Peddada S, Amir A, Bittinger K, Gonzalez A, Lozupone C, Zaneveld JR,
720 Vázquez-Baeza Y, Birmingham A, et al. Normalization and microbial differential abundance
721 strategies depend upon data characteristics. Microbiome 2017; 5:27.
- 722 87. Paulson J. metagenomeSeq: Statistical analysis for sparse high-throughput sequencing.
723 BioconductorJp 2014; :1–20.
- 724 88. Team RC. R: A language and environment for statistical title.
- 725 89. McMurdie PJ, Holmes S. phyloseq: an R package for reproducible interactive analysis and
726 graphics of microbiome census data. PLoS One 2013; 8:e61217.
- 727 90. Dixon P. VEGAN, a package of R functions for community ecology. Journal of Vegetation
728 Science 2003; 14:927–30.
- 729 91. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-
730 seq data with DESeq2. Genome Biol 2014; 15:550.
- 731 92. Andersen KS, Kirkegaard RH, Karst SM, Albertsen M. ampvis2: an R package to analyse
732 and visualise 16S rRNA amplicon data. bioRxiv 2018;
- 733 93. Wickham H. ggplot2. Wiley Interdiscip Rev Comput Stat 2011; 3:180–5.

734

735




Figure 1: Overview of mouse phenotypic characteristics. A) Weight gain percentage of the mice treated with the four different FVT treatments. B) Measure of epididymal white adipose tissue isolated from mice from the different FVT treatment groups. C) and D) Oral glucose tolerance test (OGTT) and total area under the curve (tAUC) measured 10 weeks after second FVT (23 weeks old) of the different FVT treatment groups. E) Cumulative score and representative histology images of liver tissue evaluating the effect of the different FVT treatments related to liver pathology. Significant changes compared to LFD-control treatment, HFD-control, and FVT-UnT are marked by (a), (b), and (c), respectively. Scale in histology images = 300 μ m.





Figure 2: Immune cell count in fat tissue at study termination. A) to L) are showing the overall fluorescence-activated cell sorter (FACS) profile in the mouse fat tissue of the different FVT treatments. Significant changes compared to LFD-control treatment, HFD-control and FVT-UnT are marked by (a), (b), and (c), respectively.



748

749 Figure 3: Bacteriome analysis based on 16S rRNA gene amplicon sequencing. A) The general bacterial Shannon diversity
 750 index (alpha diversity), B) bray-curtis dissimilarity based PCoA plot (beta diversity) and C) heatmap representing the
 751 relative abundance of dominating bacterial taxa at arrival (before diet intervention, age week 5), one week after the second
 752 FVT (1w after 2nd FVT, age week 14), and termination (age week 23). Significant changes compared to LFD-control
 753 treatment, HFD-control and FVT-UnT are marked by (a), (b), and (c), respectively.




Figure 4: Metavirome analysis based on whole-genome sequencing of viral entities. A) The general viral Shannon diversity indexes (alpha diversity), B) Bray-curtis dissimilarity based PCoA plot (beta diversity), C) heatmap representing the relative abundance of dominating viral taxa at arrival (before diet intervention, age week 5), one week after the second FVT (1w after 2nd FVT, age week 14), and termination (age week 23). Significant changes compared to LFD-control treatment, HFD-control and FVT-UnT are marked by (a), (b), and (c), respectively.




Figure 5: Overview of the animal model. Forty-eight male C57BL/6NTac mice (5 weeks old) were divided into six groups. The mice were fed with either low-fat diet and high-fat diet. After six and seven weeks on a high-fat diet, the mice were treated with either FVT-UnT (fecal virome transplantation with untreated sterile filtered donor feces from healthy mice), FVT_ChP (FVT with chemostat propagation of fecal donor virome to remove eukaryotic viruses by gradient dilution), FVT_SDT (FVT with solvent detergent treatment to inactivate enveloped viruses), and FVT_PyT (FVT with pyronin Y treatment to inactivate RNA viruses), or a saline solution as sham. Oral glucose tolerance tests (OGTT) were measured at week 18 and 23 of age. The brown crosses mark the timepoint of feces samples that were used for gut microbiome analysis.